Loading stock data…
URGN
$23.00-0.83 (-3.48%)
Market ClosedLast close May 1
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
UroGen Pharma Ltd. in the Healthcare sector is trading at $23.00. The stock is currently 23% below its 52-week high of $30.00, remaining 12.4% above its 200-day moving average. Technical signals show neutral RSI of 63 and bearish MACD signal, explaining why URGN maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.00
Potential Upside
5%
Whystock Fair Value$24.15
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technolog...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.44
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
145.53%
Volume
Today's trading volume
794,689
Recent News
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady
UroGen Pharma’s latest analyst update keeps the fair value target effectively anchored at US$35.63, with no reset in the central valuation estimate. Bullish voices see this as support for a constructive risk and reward setup, while more cautious analysts point to the unchanged fair value as a reason to wait for clearer clinical or commercial evidence. As you read on, you will see how to track these shifting views and what signals to watch as the narrative develops. Stay updated as the Fair...
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities
UroGen Pharma’s fair value estimate holds at US$35.63, with recent model tweaks leaving the price target itself unchanged. Analysts are using recent moves in other healthcare names, where cost pressures, technical updates, and financing choices affected targets, as a reference point for factors that could eventually influence UroGen’s valuation story. As you read on, you will see how bullish and bearish voices are interpreting these signals and what to watch to stay on top of the evolving...
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.